Sagent Pharmaceuticals Recalls Methylprednisolone Sodium Succinate for Injection

Article

The company is recalling Methylprednisolone Sodium Succinate for Injection, USP, 40mg, 125mg, and 1g manufactured by Gland Pharma Ltd and distributed by Sagent due to out-of-specification impurity results.

On March 5, 2018, Sagent Pharmaceuticals announced it is recalling 10 lots of Methylprednisolone Sodium Succinate for Injection, USP, 40mg, 125mg, and 1g manufactured by Gland Pharma Ltd and distributed by Sagent. The recall was initiated after the discovery of high out-of-specification impurity results found during routine quality testing of stability samples for two lots.

The recalled lots were distributed to hospitals, wholesalers, and distributors nationwide from April 2017 through February 2018. At the time of the recall announcement, Sagent was not aware of any adverse events resulting from the recalled product. Adverse events may be reported to FDA’s MedWatch program.

Methylprednisolone Sodium Succinate for Injection, USP is an anti-inflammatory glucocorticoid used to treat multiple conditions including dermatologic diseases, endocrine disorders, and hematologic disorders. According to the company, elevated impurity may decrease the effectiveness of the product.

Source: FDA

 

Recent Videos
Simon Wright from Almac Pharma Services chats about shifting demand for commercial manufacturing services and how service providers are adapting to meet demand.
Ian Lafferty from Upperton discusses the trends and challenges facing sterile manufacturing and how partnering with CDMOs can help innovators progress to the market.
Kate Coleman, vice president regulatory affairs, quality and compliance, Arriello, chats about industry trends and technological advances.
Industry Outlook 2025: The Rising Prominence of AI in Pharma
Adam Sherlock, CEO of Qinecsa, discusses the changing political landscapes in the US and Europe and how that may affect the bio/pharma industry.
Related Content
© 2025 MJH Life Sciences

All rights reserved.